Electromed, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2014. The supplied metadata identifies “2013 Q3,” but the filing is for Electromed’s fiscal third quarter of 2014. The filing was signed May 14, 2014. Electromed develops, manufactures, and markets High Frequency Chest Wall Oscillation airway-clearance products, including the SmartVest system, for home-care, institutional, government, and international markets.
Financial Results and Position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net revenues | $3.956 million, up 23.7% | $10.876 million, down 1.9% |
| Gross profit | $2.520 million; 63.7% margin | $7.399 million; 68.0% margin |
| Operating loss | $0.217 million; approximately 5.5% operating margin | $1.103 million; approximately 10.1% operating margin |
| Net loss | $1.004 million, or $0.12 per share | $1.579 million, or $0.19 per share |
| Operating cash flow | Not separately reported for the quarter | $1.020 million provided |
Quarterly revenue growth reflected higher home-care approvals and average selling price, increased international sales, and higher government/institutional revenue. Quarterly gross profit increased modestly, but gross margin declined substantially because of referral mix and startup inefficiencies in sourcing and manufacturing the new SmartVest SQL product.
As of March 31, 2014, cash and cash equivalents were $772,000, current assets were $10.771 million, and current liabilities were $2.412 million, producing working capital of approximately $8.359 million and a current ratio of approximately 4.5. Accounts receivable declined to $6.470 million from $9.014 million at June 30, 2013, while inventories increased to $2.551 million from $1.380 million.
Total debt was approximately $1.309 million, consisting of $46,000 of current maturities and $1.263 million of long-term debt. No principal was outstanding under the $2.5 million revolving line of credit at March 31, 2014, and the company reported $2.5 million of net unused availability. The line of credit expires December 18, 2014, if not renewed.
Material Changes Versus Prior Comparable Period
- Quarterly revenue increased $757,000, led by home-care revenue growth of 23.6%, international growth of 34.4%, and government/institutional growth of 18.0%.
- Nine-month revenue declined $210,000, primarily because home-care revenue fell 5.3% as a result of lower average selling prices, fewer referrals, reimbursement pressure, and longer payer approval processes. International revenue increased 6.0%, and government/institutional revenue increased 25.1%.
- Nine-month gross margin decreased from 70.2% to 68.0%; management attributed the decline principally to lower pricing and SQL manufacturing inefficiencies.
- SG&A decreased 13.2% for the quarter and 8.5% for the nine-month period, reflecting lower payroll, professional fees, advertising, and travel expenses. Prior-year professional fees included one-time information-technology, shareholder-proposal, and litigation-related costs.
- Nine-month research and development expense increased 29.8% to $405,000 as the company finalized development and testing of the SmartVest SQL.
- The company recorded a $454,000 discrete tax expense in the nine-month period, primarily from establishing a full valuation allowance against U.S. federal and state deferred tax assets. This contributed to the reported net loss; management stated that adjusted net loss excluding this noncash valuation allowance was approximately $736,000 for the nine months and $161,000 for the quarter.
- Cash provided by operations increased modestly from $990,000 to $1.020 million despite the larger reported net loss, principally because of collections of accounts receivable and noncash adjustments.
Guidance, Outlook, Risks, and Unusual Items
- The FDA cleared the SmartVest SQL in December 2013, and Electromed began domestic home-care sales in January 2014. Management expects limited short-term revenue impact because reimbursement approvals take time.
- Management expects long-term gross margins to return to approximately 70% as sales scale and manufacturing efficiencies improve. It expects research and development spending to remain approximately 3% to 5% of revenue over the long term.
- The principal operating risk is reimbursement: third-party payer pricing pressure, additional administrative procedures, longer approval cycles, and continuing contracting work with Blue Cross and Blue Shield affiliates could reduce revenue and cash flow.
- The company was in violation of its minimum tangible net worth covenant for the quarter ended March 31, 2014; the bank waived the resulting event of default. On May 6, 2014, the covenant was amended, reducing the minimum tangible net worth requirement from $12.0 million to $10.125 million.
- Management believes operating cash flow and credit availability will support liquidity for the next year, but renewal of the revolving facility or alternative financing will be necessary before its December 18, 2014 expiration. There is no assurance that financing will be available on favorable terms.
- Future covenant violations, failure to renew the credit line, or acceleration of debt could restrict access to funds, require repayment, and potentially threaten continued operations. The credit facility is secured by substantially all tangible and intangible assets, and the term loan is secured by company real property.
- Management received approximately $100,000 of insurance reimbursement in April 2014 for litigation-related professional fees and believes additional reimbursement may be possible, but no specific additional amount is guaranteed.
- The company recorded a warranty reserve of $740,000 at March 31, 2014, up from $680,000 at June 30, 2013. It reported no material undisclosed litigation and no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Whether SQL adoption and reimbursement approvals produce sustained home-care revenue growth and restore gross margins.
- Progress in resolving remaining payer contracting issues and the effect of reimbursement pricing and approval delays.
- Compliance with the amended $10.125 million tangible net worth covenant and the status of credit-line renewal or replacement financing before December 18, 2014.
- Whether deferred tax assets become realizable and whether the $454,000 valuation allowance is reversed or increased in future periods.
- Inventory growth, warranty-reserve adequacy, and the sustainability of positive operating cash flow while the company remains unprofitable.
- The terms and financial impact of the May 6, 2014 credit-facility amendment and any additional insurance recovery related to settled litigation.